www.hivandhepatitis.com

Back HCV Disease Progression

EASL 2017: Direct-Acting Antivirals for Hepatitis C Not Linked to Higher Liver Cancer Risk

Details
Category: HCV Disease Progression
Published on Thursday, 20 April 2017 00:00
Written by Liz Highleyman
  • Print

Hepatitis C patients treated with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher rates seen in some studies are attributable to risk factors such as older age and more advanced liver disease, according to a set of studies presented at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

More Articles...

  1. CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?
  2. AASLD 2016: Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?
  3. AASLD 2016: Curing Hepatitis C Reduces Liver-Related Complications and Death
  4. AASLD 2016: Liver Cirrhosis and Decompensation on the Rise Among People with Hepatitis C
  5. AASLD 2016: Curing Hepatitis C May Help Reduce Kidney Disease Progression

Subcategories

Copyright © 2023 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design